An update on neuroimaging of multiple sclerosis

Current Opinion in Neurology

Volumn 17, Issue 4, 2004, Pages 453-458

  Matthews, Paul M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

fMRI; Molecular imaging; MRI; Multiple sclerosis; PET

Indexed keywords

CASPASE 10; CASPASE 8; CONTRAST MEDIUM; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; INTERLEUKIN 10; MESSENGER RNA; MOLECULAR MARKER; N ACETYLASPARTIC ACID; TUMOR NECROSIS FACTOR ALPHA;

AXONAL INJURY; BRAIN ATROPHY; CLINICAL TRIAL; COGNITIVE DEFECT; GENETIC HETEROGENEITY; GRAY MATTER; HUMAN; MOTOR SYSTEM; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; PHYSICAL DISABILITY; REMYELINIZATION; REVIEW; THALAMUS;

BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM; CONTRAST MEDIA; DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; NERVE DEGENERATION;

EID: 4043120322     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wco.0000137537.06986.b0     Document Type: Review

References (55)

1. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50:121-127.
2. Frohman EM, Goodin DS, Calabresi PA, et al. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003; 61:602-611. The McDonald criteria [1] were not intended to be unchanging: the original proposal acknowledged the limited information on which specific recommendations were based. This committee report proposes revisions in application to make the MRI changes necessary for diagnosis of MS less stringent in order to enhance sensitivity.
3. Wayne Moore GR. MRI-clinical correlations: more than inflammation alone - what can MRI contribute to improve the understanding of pathological processes in MS? J Neurol Sci 2003; 206:175-179.
4. Cotton F, Weiner HL, Jolesz FA, Guttmann CR. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003; 60:640-646.
5. Meier DS, Guttmann CR. Time-series analysis of MRI intensity patterns in multiple sclerosis. Neuroimage 2003; 20:1193-1209.
6. Adalsteinsson E, Langer-Gould A, Homer RJ, et al. Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis. Am J Neuroradiol 2003; 24:1941-1945.
7. Wylezinska M, Cifelli A, Jezzard PM, et al. Thalamic neurodegeneration in relapsing-remitting multiple sclerosis. Neurology 2003; 60:1949-1954. Evidence that neuronal loss in thalamic grey matter progresses from the earliest stages of the disease.
8. Vaithianathar L, Tench CR, Morgan PS, Constantinescu CS. Magnetic resonance imaging of the cervical spinal cord in multiple sclerosis - a quantitative T1 relaxation time mapping approach. J Neurol 2003; 250:307-315.
9. Turner B, Lin X, Calmon G, et al. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years. Mult Scler 2003; 9:21-27.
10. Sailer M, Fischl B, Salat D, et al. Focal thinning of the cerebral cortex in multiple sclerosis. Brain 2003; 126:1734-1744. An elegant study that provides clear evidence that cortical atrophy in MS is variable across different brain regions. Detecting regional changes may prove to be more sensitive to progression than measurement of global atrophy rates. Understanding the basis of this generation may provide important clues to the genesis of neuroaxonal injury in MS.
11. Cifelli A, Arridge M, Jezzard P, et al. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002; 52:650-653.
12. Kassubek J, Tumani H, Ecker D, et al. Age-related brain parenchymal fraction is significantly decreased in young multiple sclerosis patients: a quantitative MRI study. Neuroreport 2003; 14:427-430.
13. Grace EA, Busciglio J. Aberrant activation of focal adhesion proteins mediates fibrillar amyloid beta-induced neuronal dystrophy. J Neurosci 2003; 23:493-502.
14. Grace EA, Rabiner CA, Busciglio J. Characterization of neuronal dystrophy induced by fibrillar amyloid beta: implications for Alzheimer's disease. Neuroscience 2002; 114:265-273.
15. Lombardo JA, Stern EA, McLellan ME, et al. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci 2003; 23:10879-10883. Dendritic arborization can change reversibly in neurodegenerative diseases. Mechanisms that give rise to brain atrophy need not be irreversible.
16. Shim KS, Lubec G. Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer's disease and Down syndrome. Neurosci Lett 2002; 324:209-212.
17. Le R, Cruz L, Urbanc B, et al. Plaque-induced abnormalities in neurite geometry in transgenic models of Alzheimer disease: implications for neural system disruption. J Neuropathol Exp Neurol 2001; 60:753-758.
18. Grill JD, Riddle DR. Age-related and laminar-specific dendritic changes in the medial frontal cortex of the rat. Brain Res 2002; 937:8-21.
19. Evangelou N, Konz D, Esiri MM, et al. Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain 2000; 123:1845-1849.
20. Casanova B, Martinez-Bisbal MC, Valero C, et al. Evidence of Wallerian degeneration in normal appearing white matter in the early stages of relapsing-remitting multiple sclerosis: a HMRS study. J Neurol 2003; 250:22-28.
21. Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003; 126:433-437.
22. Helms G, Stawiarz L, Kivisakk P, Link H. Regression analysis of metabolite concentrations estimated from localized proton MR spectra of active and chronic multiple sclerosis lesions. Magn Reson Med 2000; 43:102-110.
23. Wilson M, Tench CR, Morgan PS, Blumhardt LD. Pyramidal tract mapping by diffusion tensor magnetic resonance imaging in multiple sclerosis: improving correlations with disability. J Neurol Neurosurg Psychiatry 2003; 74:203-207. An intelligent attempt to use functional anatomical information from diffusion tractography to define system-specific axonal loss in MS.
24. Behrens TE, Johansen-Berg H, Woolrich MW, et al. Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat Neurosci 2003; 6:750-757. A beautiful demonstration of the potential of probabilistic tractography (using diffusion MRI) for defining brain regions on the basis of anatomical connectivities. Although a study of the healthy brain, it is easy to appreciate how this approach could be extended to provide a quantitative method for study of MS.
25. Behrens TE, Woolrich MW, Jenkinson M, et al. Characterization and propagation of uncertainty in diffusion-weighted MR imaging. Magn Reson Med 2003; 50:1077-1088.
26. Henry RG, Oh J, Nelson SJ, Pelletier D. Directional diffusion in relapsing-remitting multiple sclerosis: a possible in vivo signature of Wallerian degeneration. J Magn Reson Imaging 2003; 18:420-426.
27. Charil A, Zijdenbos AP, Taylor J, et al. Statistical mapping analysis of lesion location and neurological disability in multiple sclerosis: application to 452 patient data sets. Neuroimage 2003; 19:532-544. A thought-provoking use of probabilistic lesion mapping techniques to correlate regional lesion loads with specific clinical syndromes.
28. Evangelou N, Jackson M, Beeson D, Palace J. Association of the APOE epsilon4 allele with disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999; 67:203-205.
29. Enzinger C, Ropele S, Smith S, et al. Accelerated evolution of brain atrophy and "black holes" in MS patients with APOE-e4. Ann Neurol 2004; 55:563-569. This report further defines a specific genetic determinant of the severity of pathology in MS with demonstration that patients with the apolipoprotein E4 haplotype show substantially faster progression of brain atrophy and have a higher proportion of T1-hypointense (relative to T2-hyperintense) lesions.
30. Bagnato F, Jeffries N, Richert ND, et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain 2003; 126:1782-1789.
31. Bruck W, Kuhlmann T, Stadelmann C. Remyelination in multiple sclerosis. J Neurol Sci 2003; 206:181-185.
32. Barkhof F, Bruck W, De Groot CJ, et al. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol 2003; 60:1073-1081.
33. Gomes AC, Morris M, Stawiarz L, et al. Decreased levels of CD95 and caspase-8 mRNA in multiple sclerosis patients with gadolinium-enhancing lesions on MRI. Neurosci Lett 2003; 352:101-104.
34. Sibson NR, Blamire AM, Bernades-Silva M, et al. MRI detection of early endothelial activation in brain inflammation. Magn Reson Med 2004; 51:248-252. A carefully performed animal study demonstrating the potential for targeting gadolium chelates as contrast agents for specific cell surface determinants.
35. Rausch M, Hiestand P, Baumann D, et al. MRI-based monitoring of inflammation and tissue damage in acute and chronic relapsing EAE. Magn Reson Med 2003; 50:309-314. An elegant and potentially general approach to imaging specfic cell-surface molecules is described, using antibody-mediated targeting of MRI contrast.
36. Banati RB, Newcombe J, Gunn RN, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000; 123:2321-2337.
37. Debruyne JC, Versijpt J, Van Laere KJ, et al. PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. Eur J Neurol 2003; 10:257-264. This reference provides non-invasive evidence for widepread microglial activation in MS. Such data eventually should elucidate whether the neuroaxonal injury that mediates the progression of disability is a direct consequence of inflammatory activity in lesions or of more diffuse changes.
38. Tofts PS. Optimal detection of blood-brain barrier defects with Gd-DTPA MRI - the influences of delayed imaging and optimised repetition time. Magn Reson Imaging 1996; 14:373-380.
39. Silver NC, Tofts PS, Symms MR, et al. Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study. Mult Scler 2001; 7:75-82.
40. Inglese M, Li BS, Rusinek H, et al. Diffusely elevated cerebral choline and creatine in relapsing-remitting multiple sclerosis. Magn Reson Med 2003; 50:190-195.
41. Filippi M, Rocca MA. Disturbed function and plasticity in multiple sclerosis as gleaned from functional magnetic resonance imaging. Curr Opin Neurol 2003; 16:275-282.
42. Cifelli A, Matthews PM. Cerebral plasticity in multiple sclerosis: insights from fMRI. Mult Scler 2002; 8:193-199.
43. Reddy H, Narayanan S, Arnoutelis R, et al. Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis. Brain 2000; 123:2314-2320.
44. Reddy H, Narayanan S, Woolrich M, et al. Functional brain reorganization for hand movement in patients with multiple sclerosis: defining distinct effects of injury and disability. Brain 2002; 125:2646-2657.
45. Lee M, Reddy H, Johansen-Berg H, et al. The motor cortex shows adaptive functional changes to brain injury from multiple sclerosis. Ann Neurol 2000; 47:606-613.
46. Reddy H, Narayanan S, Matthews PM, et al. Relating axonal injury to functional recovery in MS. Neurology 2000; 54:236-239.
47. Rocca MA, Mezzapesa DM, Falini A, et al. Evidence for axonal pathology and adaptive cortical reorganization in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis. Neuroimage 2003; 18:847-855. Evidence suggesting that adaptive functional reorganization is an early change with the progression of pathology, consistent with the notion that it delays progression.
48. Rocca MA, Matthews PM, Caputo D, et al. Evidence for widespread movement-associated functional MRI changes in patients with PPMS. Neurology 2002; 58:866-872.
49. Rocca MA, Pagani E, Ghezzi A, et al. Functional cortical changes in patients with multiple sclerosis and nonspecific findings on conventional magnetic resonance imaging scans of the brain. Neuroimage 2003; 19:826-836.
50. Rocca MA, Gavazzi C, Mezzapesa DM, et al. A functional magnetic resonance imaging study of patients with secondary progressive multiple sclerosis. Neuroimage 2003; 19:1770-1777.
51. Pantano P, Iannetti GD, Caramia F, et al. Cortical motor reorganization after a single clinical attack of multiple sclerosis. Brain 2002; 125:1607-1615.
52. Penner IK, Rausch M, Kappos L, et al. Analysis of impairment related functional architecture in MS patients during performance of different attention tasks. J Neurol 2003; 250:461-472.
53. Parry AM, Scott RB, Palace J, et al. Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Brain 2003; 126:2750-2760. An important study emphasizing that altered patterns of brain activation in disease can be modulated rapidly. The study also illustrates how functional MRI could be used as a method for early screening of drugs with a potential for improving neuronal function after injury with MS. Acetylcholinesterase inhibition is proposed as a candidate treatment for cognitive dysfunction in MS.
54. Rovaris M, Comi G, Ladkani D, et al. Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis. Am J Neuroradiol 2003; 24:75-81.
55. Sormani MP, Bruzzi P, Beckmann K, et al. MRI metrics as surrogate endpoints for extended disability status scale progression in SPMS patients treated with IFN beta-1b. Neurology 2003; 60:1462-1466. A quantitative test of the explanatory power of conventional MRI measures of pathological change in a therapeutically successful drug study. The results emphasize that currently popular MRI measures explained only just over half of the clinical effect.